Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carlos Matute Martinez

Internal Medicine New Haven, CT Medical Doctor

NPI 1568023026 CMS profile 7017416

20 York St, New Haven, CT 06510

Open in the dashboard

General payments

$5,483

80 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carlos Matute Martinez of New Haven, CT is reported in the CMS Open Payments database as having received $5,483 across 80 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,702 38
2024 General $1,341 25
2023 General $1,030 12
2022 General $104 2
2020 General $211 2
2019 General $95 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carlos Matute Martinez
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Carlos Matute Martinez were reported at $2,702. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Carlos Matute Martinez Internal Medicine median Middle half National median
2019 $95 $159 $48–$570 $163
2020 $211 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $104 $141 $42–$496 $149
2023 $1,030 $149 $45–$519 $160
2024 $1,341 $154 $47–$537 $164
2025 $2,702 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Philips Electronics North America Corporation $1,125 5 payments
  2. Abiomed $1,063 12 payments
  3. Medtronic, Inc. $582 7 payments
  4. Abbott Laboratories $545 5 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $279 4 payments
  6. Pfizer Inc. $274 8 payments
  7. Merck Sharp & Dohme Corporation $230 11 payments
  8. Alnylam Pharmaceuticals Inc. $219 5 payments
  9. Actelion Pharmaceuticals US, Inc. $178 2 payments
  10. Boston Scientific Corporation $135 1 payment
  11. Other $853 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,992 72 payments
  2. Travel and Lodging $1,125 5 payments
  3. Education $367 3 payments
Products named General payments · program years 2019–2025
  1. IGT Devices Undivided $1,125 5 payments
  2. Impella $743 7 payments
  3. VERQUVO $311 15 payments
  4. ENSITE $286 1 payment
  5. LifeVest $279 4 payments
  6. VYNDAQEL $274 8 payments
  7. AMVUTTRA $219 5 payments
  8. CARDIOMEMS $209 2 payments
  9. OPSUMIT $178 2 payments
  10. UPTRAVI $178 2 payments
  11. Other $1,771 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

57

Median for Student in an Organized Health Care Education/Training Program: 43

Drug cost

$533

Median for Student in an Organized Health Care Education/Training Program: $442

Branded share of claims

21.1%

Median for Student in an Organized Health Care Education/Training Program: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rosuvastatin Calcium Generic 15 $157
Atorvastatin Calcium Generic 16 $155
Metoprolol Succinate Generic 14 $136
Clopidogrel Clopidogrel Bisulfate Brand 12 $85

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 30,207 Part D prescribers listed as Student in an Organized Health Care Education/Training Program; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
  • PFIZER INC. $235
$235 — —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $101
$101 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $92
$92 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $36
$36 — —
Wegovy
  • Novo Nordisk Inc $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

80 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record